Drug Discovery Biotechnology Company

We are an emerging biotechnology company dedicated to the discovery of small-molecule therapeutics and diagnostics for the treatment of the debilitating neurological orphan indication of amyotrophic lateral sclerosis (ALS, Lou Gehrig’s disease).  We incorporate modern aspects of drug discovery including compound library synthesis and screening.  In partnership with top academic and industrial laboratories, ALS Biopharma, LLC is researching both small molecule and biologic protein-based approaches to treat the disease.

Location and Facilities

We are located in the Pennsylvania Center for Drug Discovery at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA (www.pabiotechbc.org).

Our laboratories at the PBC include a complete array of chemistry and biochemistry tools and equipment such as a real time PCR, laminar flow hoods, table top centrifuges, Thermofinnagan LCQ and ABI Qtrap Mass Specs, Waters HPLC systems, a Biomek robot liquid handler, and other equipment that is routine for modern molecular biology, high throughput screening, and medicinal chemistry.


Press Releases and News

 

September 6, 2011: ALS Biopharma announces that it was been selected as a finalist in the Philadelphia Business Journal Life Sciences Award program.

 

March 24, 2011: ALS Biopharma is pleased to announce that the company has been granted orphan drug designationby the U.S. Food and Drug Administration for heat shock protein Hsp70 for the treatment of amyotrophic lateral sclerosis.

 

March 11, 2011: ALS Biopharma, LLC reports that MDA Venture Philanthropy has awarded the company a grant of $250,000.

 

January 27, 2011: Alzheimer's Drug Discovery Foundation Funds ALS Biopharma, LLC to Develop Small Molecules for Alzheimer's Disease

 

September 27, 2010: ALS Biopharma, LLC Established Strategic Alliance with Vybion

 

June 25, 2010: ALS Biopharma, LLC announced liscensing agreement with Wake Forest University Baptist Medical Center covering the use of the heat shock proteins for the treatment of Amyotrophic Lateral Scelrosis

 

Tree Watermark